Collaboration and Licensing Revenue (Tables)

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2017 and 2016.

	Three Months Ended March 31, 2017
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	4,842	$	6,143	$	10,985
Oragenics, Inc.	263		306		569
Fibrocell Science, Inc.	605		1,134		1,739
Genopaver, LLC	69		1,611		1,680
S & I Ophthalmic, LLC	—		303		303
OvaXon, LLC	—		824		824
Intrexon Energy Partners, LLC	625		4,461		5,086
Persea Bio, LLC	125		164		289
Ares Trading S.A.	1,597		1,718		3,315
Intrexon Energy Partners II, LLC	500		649		1,149
Intrexon T1D Partners, LLC	264		868		1,132
Harvest start-up entities (1)	601		2,762		3,363
Other	1,833		798		2,631
Total	$	11,324	$	21,741	$	33,065

(1) For the three months ended March 31, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

	Three Months Ended March 31, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	922	$	6,059	$	6,981
Oragenics, Inc.	263		543		806
Fibrocell Science, Inc.	605		1,252		1,857
Genopaver, LLC	69		1,509		1,578
S & I Ophthalmic, LLC	—		1,186		1,186
OvaXon, LLC	—		694		694
Intrexon Energy Partners, LLC	625		3,363		3,988
Persea Bio, LLC	125		199		324
Ares Trading S.A.	1,597		808		2,405
Intrexon Energy Partners II, LLC	500		50		550
Harvest start-up entities (1)	46		388		434
Other	1,020		2,250		3,270
Total	$	5,772	$	18,301	$	24,073

(1) For the three months ended March 31, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.

Summary of Deferred Revenue

Deferred revenue consists of the following:

	March 31, 2017		December 31, 2016
Upfront and milestone payments	$	287,677	$	297,867
Prepaid research and development services	3,899		6,015
Prepaid product and service revenues	5,613		5,554
Other	102		706
Total	$	297,291	$	310,142
Current portion of deferred revenue	$	50,333	$	53,364
Long-term portion of deferred revenue	246,958		256,778
Total	$	297,291	$	310,142

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.

	March 31, 2017		December 31, 2016
ZIOPHARM Oncology, Inc.	$	133,967	$	138,809
Oragenics, Inc.	7,503		7,766
Fibrocell Science, Inc.	18,421		19,026
Genopaver, LLC	1,908		1,977
Intrexon Energy Partners, LLC	17,500		18,125
Persea Bio, LLC	3,875		4,000
Ares Trading S.A.	45,581		47,178
Intrexon Energy Partners II, LLC	15,333		15,833
Intrexon T1D Partners, LLC	8,492		8,653
Harvest start-up entities (1)	19,681		20,208
Other	15,416		16,292
Total	$	287,677	$	297,867

(1) As of March 31, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.